Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
invitae in the news | 1.86 | 0.6 | 4126 | 88 | 19 |
invitae | 0.94 | 1 | 6552 | 41 | 7 |
in | 0.49 | 1 | 6545 | 81 | 2 |
the | 1.48 | 0.1 | 4085 | 44 | 3 |
news | 0.91 | 0.4 | 7282 | 97 | 4 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
invitae in the news | 1.85 | 0.5 | 6381 | 63 |
invitae stock news | 0.35 | 0.3 | 5791 | 70 |
invitae corporation news | 1.12 | 0.6 | 5178 | 33 |
davita in the news | 0.35 | 1 | 1262 | 100 |
invitae stock price today | 1.11 | 0.8 | 6162 | 2 |
invitae insurance in network | 0.3 | 0.3 | 8434 | 57 |
is invitae a buy | 1.19 | 0.7 | 5690 | 29 |
invitae stock motley fool | 0.87 | 0.8 | 8066 | 25 |
invitae corp stock forecast | 1.4 | 0.8 | 6838 | 62 |
how much does invitae cost | 1.21 | 0.8 | 1458 | 47 |
where is invitae located | 0.55 | 0.1 | 3154 | 27 |
invitae corporation stock price | 1.4 | 0.5 | 4909 | 47 |
why is invitae stock down | 0.15 | 0.3 | 7718 | 100 |
invitae in network insurances | 0.58 | 0.7 | 1145 | 54 |
invitae stock price forecast | 0.41 | 0.8 | 8221 | 46 |
invitae corp stock price | 1.55 | 1 | 3058 | 35 |
invitae stock price history | 0.49 | 0.3 | 2102 | 100 |
what analysts are saying about invitae | 0.32 | 0.7 | 8842 | 52 |
invitae board of directors | 1.82 | 0.5 | 4343 | 95 |
invitae number of employees | 1.43 | 0.4 | 2886 | 25 |
invitae australia pty ltd | 0.33 | 0.8 | 40 | 88 |
what is invitae corporation | 1.36 | 0.4 | 2067 | 8 |
invitae for healthcare providers | 1.3 | 0.4 | 7691 | 79 |
what is invitae corp | 1.53 | 0.9 | 2329 | 9 |
invitae corporation investor relations | 1.65 | 0.7 | 5347 | 49 |
The shares of Invitae Corporation ( NYSE: NVTA ) fell ~5% pre-market Tuesday after Goldman Sachs downgraded it to Sell from Neutral predicting a long path to profitability for the medical diagnostics company despite its recent efforts at restricting.
Does Invitae have a long path to profitability?Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs. The Analyst: Matthew Sykes downgraded the rating for Invitae from Neutral to Sell, while reducing the price target from $4 to $2. Check out other analyst stock ratings.
Is Invitae poised to re-accelerate growth?Invitae seems to have “a long and uncertain path towards profitability and a gross margin profile that will make it difficult to deploy opex in order to re-accelerate growth,” the analyst added.
What is the target price for Invitae Corporation (NVTA)?Invitae Corporation (NYSE:NVTA)’s beta value is holding at 1.86, while the average true range (ATR) indicator is currently reading 0.23. Considering analysts have assigned the stock a price target range of $1.00-$4.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $2.84.